Memo Ther­a­peu­tics re­fu­els with $22M to ex­pand tri­al for in­fec­tion-fight­ing an­ti­body in kid­ney trans­plant re­cip­i­ents

Swiss biotech Memo Ther­a­peu­tics raised $22 mil­lion (CHF 20 mil­lion) in a Se­ries C ex­ten­sion to de­vel­op an an­ti­body treat­ment for BK poly­omavirus (BKV) in­fec­tion in kid­ney trans­plant re­cip­i­ents, a con­di­tion that cur­rent­ly doesn’t have any ap­proved treat­ments.

Last year, Memo raised about $27.6 mil­lion (CHF 25 mil­lion) in a Se­ries C fi­nanc­ing round, bring­ing the to­tal raised for the com­pa­ny to $49.6 mil­lion (CHF 45 mil­lion). Ys­ios Cap­i­tal and Kur­ma Part­ners par­tic­i­pat­ed in the ex­ten­sion round, join­ing ex­ist­ing in­vestors that in­clud­ed Pure­os Bioven­tures and Swiss­canto, among oth­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER